PDA initiative connecting drug manufacturers, glass suppliers to make manufacturing great
First initiative is to eliminate visible particles from parenteral products,
The Parenteral Drug Association (PDA) has announced a significant initiative to bring together executives, including CEOs and executive vice presidents, from biologic and pharmaceutical manufacturers with glass container and elastomeric closure suppliers to prepare industry for the complex products and manufacturing processes of the future. They aspire to achieve this through collective and collaborative continuous improvement projects to take today's world-class injectable medicine manufacturing to the next level.
Their first initiative is to eliminate visible particles from parenteral products. Since December, a PDA task force, consisting of multidisciplinary members from biologic and pharmaceutical manufacturers and suppliers of glass container and elastomeric closures with more than 1,000 years of experience combined, has been meeting with a focus on the entire supply chain from raw materials to finished product. This initiative represents an audacious goal, and will only succeed with all affected parties working collaboratively toward the objective of eliminating visible particles.
PDA is also proud to announce a memorandum of understanding with the BioPhorum Operations Group who has worked with a team of professionals to improve the performance of rubber closures for parenteral products. The memorandum of understanding expands the collaboration and accelerates the development of best practices and standards, while striving to avoid the development of conflicting approaches.
Patients will be the key beneficiary from this effort to ensure quality medicines are delivered in a robust and reliable supply chain. The goals of the initiative epitomizes PDA's mission to advance pharmaceutical / biopharmaceutical manufacturing science and regulation so its members can better serve patients.
The initiative was made possible by PDA Chairman of the Board, Martin VanTrieste, who worked diligently to persuade over 40 executives representing over 30 companies to come to Bethesda, Maryland to join forces and work together to serve patients. These executives committed the necessary resources to staff the initiative with subject-matter experts consisting of manufacturing professionals, supply chain professionals, quality professionals, engineers, scientist and physicians.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance